

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

INSIDE INFORMATION PROFIT WARNING

This announcement is made by China Pioneer Pharma Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In view of the segment losses from sales of personal protective materials, including impairment losses on inventories and trade receivables, based on the preliminary review of the information of the Group for the year ended 31 December 2020 (the “**Reporting Period**”) currently available, the Group is expected to record a decrease in net profit of approximately 45% to 55% in the Reporting Period as compared with the previous year.

The information contained in this announcement is only based on a preliminary assessment with reference to the financial information currently available and is subject to change. As of the date of this announcement, the auditing of the results of the Reporting Period has not been finalised. The auditing of the results of the Reporting Period is expected to be finalised on or before 31 March 2021, and the audited figures of the results of the Company in the Reporting Period will be set out in its 2020 annual results announcement and annual report, which are scheduled to be published on 31 March 2021 and on or before 30 April 2021, respectively.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Pioneer Pharma Holdings Limited
LI Xinzhou
Chairman

Hong Kong, 22 March 2021

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou, Mr. LUO Chunyi and Mr. XIAO Guoguang as executive directors, Mr. WU Mijia and Ms. HU Mingfei as non-executive directors and Mr. ZHANG Hong, Mr. WANG Yongli and Mr. WONG Chi Hung, Stanley as independent non-executive directors.